EMMANUEL MBI: Open Payments
NPI 1528703261 · ARLINGTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,400 in 30 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $252 · 2025 $1,400
Food & beverage: $1,296Education: $104
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $398 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $315 |
| Teva Pharmaceuticals USA, Inc. | 6 | $301 |
| E.R. Squibb & Sons, L.L.C. | 5 | $177 |
| Otsuka America Pharmaceutical, Inc. | 2 | $136 |
| ABBVIE INC. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Almatica Pharma LLC | 1 | $22 |
Products named: INVEGA SUSTENNA, CAPLYTA, COBENFY, AUSTEDO XR, REXULTI, UZEDY, VRAYLAR, FANAPT.
Industry payments across TX — which companies pay providers there.
